Suzette Tauber

Role: Chief Human Resources Officer at Igm Biosciences, Inc
Location: Mountain View, CA, US
LinkedIn followers: 500 followers

Human ResourcesView LinkedIn profile

About Suzette Tauber

Strategic HR Executive with 30+ years of experience driving organizational growth…

Experience

Chief Human Resources Officer
Igm Biosciences, Inc
Jun 2021 — Present

Education

Northern Arizona University
BA, Communications, Hospitality Management

Skills

Deferred Compensation
Human Resources
Management
Employee Relations
Strategy
Performance Management
Workforce Planning
Recruiting
Organizational Development
Benefits Administration
Start-Ups
Employee Benefits
Personnel Management
Sourcing
Hris

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
s••••••@igmbio.com
Personal email
•••••@•••••.com
Direct dial
+16•••••••99

Unlock verified contacts

Free to start · No credit card required

Current company

Igm Biosciences, Inc

Biotechnology Research · 67 employees · Founded 2010 · Mountain View, California, United States

About IGM Biosciences, Inc. IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites, compared to conventional IgG antibodies with only 2 binding sites. We have created unique IgM antibodies with high selectivity, affinity, and avidity that may redefine what is possible for therapeutic antibody medicines. We are committed to exploring how the unique structure and binding properties of the IGM antibody can improve outcomes for patients with these serious conditions. The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology, immunology, and inflammation targets. For more information, please visit Imvotamab in Autoimmune and Inflammatory Diseases Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. We believe that Imvotamab, with its 10 binding units for CD20, may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. Our preclinical studies suggest that Imvotamab may offer the potential for deeper depletion of B cells, including those in low CD20 expressing cells, than currently approved antibody therapies. We are evaluating Imvotamab in Phase 1b clinical trials of Imvotamab in severe systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and idiopathic inflammatory myopathies (myositis).

igmbio.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Suzette Tauber

Experience

Chief Human Resources Officer

Education

Northern Arizona University

Skills

Find verified contacts for anyone on LinkedIn